Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Goy Shares Insight on Novel Therapies in MCL

October 25th 2017

Andre Goy, MD, discusses the excitement surrounding novel therapies on the horizon in MCL.

Triplet Regimen Active Against Relapsed/Refractory Pediatric AML

October 25th 2017

The combination of clofarabine, cyclophosphamide, and etoposide reached an overall response rate of 41% in a small study of children and adolescents with relapsed/refractory acute myeloid leukemia.

Dr. Winter on Checkpoint Inhibitors for Hodgkin Lymphoma

October 25th 2017

Jane N. Winter, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses checkpoint inhibitors for Hodgkin lymphoma.

Carfilzomib Effective in Myeloma at Less Frequent, Higher Dose

October 24th 2017

Higher-dose, once-weekly carfilzomib (Kyprolis) demonstrated superior efficacy for patients with relapsed/refractory multiple myeloma compared with a lower-dose, twice-weekly regimen.

DLBCL Landscape Shifts Dramatically With Axicabtagene Ciloleucel FDA Approval

October 24th 2017

Reem Karmali, MD, discusses ongoing key trials of CAR T-cell therapy, the chronic safety concerns with the treatment, and what combinations have the most potential.

Dr. Karmali Discusses Toxicites Associated With CAR T-Cell Therapies

October 20th 2017

Reem Karmali, MD, assistant professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses the toxicities associated with the use of chimeric antigen receptor (CAR) T-cell therapies.

CAR T-Cell Approvals Leading Landscape of Hematologic Cancers

October 20th 2017

Andre Goy, MD, discusses the recent success with CAR T-cell therapy, and what is on the horizon for this therapeutic option across hematologic malignancies.

Rituximab Maintenance After ASCT Prolongs Survival in MCL

October 19th 2017

Maintenance rituximab (Rituxan) following autologous stem-cell transplantation improved survival in younger patients with mantle cell lymphoma, according to the LyMa trial.

FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma

October 19th 2017

The FDA has approved the CD19-directed CAR T-cell therapy axicabtagene ciloleucel as a treatment for adults with relapsed or refractory non-Hodgkin lymphoma.

Dr. Maloney Discusses Excitement With CAR T-Cell Therapy

October 18th 2017

David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center, Washington, discusses excitement with CAR T-cell therapy.

Dr. Shah Discusses Autologous Transplant in MCL

October 18th 2017

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses autologous stem cell transplant (ASCT) in mantle cell lymphoma (MCL).

Dr. Young Discusses Using Anticoagulants in Children With Cancer

October 17th 2017

Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, USC, discusses using anticoagulants in children with cancer.

Expert Discusses Ongoing Advances in CLL

October 17th 2017

Farrukh Awan, MD, discusses novel agents and combinations in CLL, as well as the critical importance of FISH and IGHV testing for patient selection in this population.

Expert Shares Insight on Developments in T-Cell Lymphoma

October 12th 2017

Jonathan Brammer, MD, discusses exciting therapeutic developments for patients with T-cell lymphoma.

Dr. Eskelund on Outcomes of TP53-Mutated MCL

October 11th 2017

Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses outcomes for patients with TP53-mutated mantle cell lymphoma (MCL).

Copanlisib Induces Nearly 1-Year Median PFS in Heavily Pretreated Indolent Lymphoma

October 11th 2017

Treatment with copanlisib led to a median progression-free survival of 11.2 months and objective response rate of 59.2% in patients with relapsed/refractory indolent lymphoma.

Dr. Wierda Discusses the Need for Newer Therapies in CLL

October 11th 2017

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the need for newer therapies in the treatment of chronic lymphocytic leukemia.

Dr. LeBlanc on Incorporating Palliative Care in the Treatment of Hematologic Malignancies

October 11th 2017

Thomas W. LeBlanc, MD, MA, medical oncologist, palliative care physician, Duke Cancer Institute, gives advice on incorporating palliative care in the treatment of hematologic malignancies.

FDA Grants Gilteritinib Fast Track Designation for AML

October 11th 2017

The FDA has granted Fast Track designation to gilteritinib for adult patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia (AML).

Dr. Winter on the Promise of CAR T-Cell Therapy in Hematologic Malignancies

October 11th 2017

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the promise of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.